Knowledge Hub
Welcome to the PAN-Biotech Knowledge Hub, your central source for the latest company news, press releases, scientific publications, product innovations, awards, and biotechnology insights.
Here you will find updates on cell culture media, sera, serum-free media, buffers, water for injection (WFI), GMP manufacturing, and contract development and manufacturing (CDMO). The Newsroom also features articles on quality standards, regulatory developments, sustainability initiatives, research collaborations, and advancements in biotechnology and pharmaceutical manufacturing.
As a German manufacturer serving research institutions, biotechnology companies, and pharmaceutical organizations worldwide, PAN-Biotech shares expert knowledge, company developments, and industry achievements to support scientists, manufacturers, and partners across the life sciences sector.
Browse our latest publications to learn more about our technologies, products, services, industry recognition, and ongoing commitment to quality, innovation, and customer success.
01
Championing Quality and Speed from Research to Commercialization
CASE Studies
Proven with our customers
When the stakes were highest — an incumbent supplier exiting, a regulatory shutdown of a US site, a new private-label GMP line, a race against the clock — these companies turned to PAN-Biotech. Four partnerships, chosen examples from numerous similar cases, show the range across every grade, from RUO and for-further-manufacturing supply under PAN-Biotech to GMP production by PAN-Celltech in a dedicated EU Annex 1 facility.
02
Securing a product after a supplier discontinuation
When an incumbent supplier discontinued the product, an established owner faced an urgent gap — a new manufacturer was needed fast, with FDA product registration and full customisation. Under PAN Complete, one partner absorbed the whole transition end-to-end: registration, sourcing, production, QA/QC, labeling, storage and shipping. A supplier exit became a documented, secured supply.
03
A two-year OEM bridge after a regulatory shutdown
A regulatory shutdown took a global supplier's US manufacturing site offline. PAN-Biotech's owner committed at a trade-show booth, and in forty days — three audits, four jurisdictions, tech transfer, MBRs — went from a handshake to production-ready. Its people volunteered over the New Year to start on 2 January. Over two years PAN-Biotech delivered ~300,000 bottles across ~25 products, with no rejections recorded, until the customer's own site recovered.
04
A global manufacturer's private-label GMP line for Europe
A global, Japan-headquartered company set out to launch a private-label product line for European customers under GMP (EU Annex 1). PAN-Celltech built a tailored CMO/CDMO model — GMP process development for new and existing products, custom single-use packaging, full QC/QA, and GDP-ready handling — integrating into the partner's existing GMP environments. Now in ongoing supply.
05
50,000 litres of GMP supply in under five weeks
A vaccine manufacturer needed large-volume GMP supply on a timeline measured in weeks. PAN-Biotech quoted in three days, began production three weeks after the order, delivered the first shipment within two weeks, and completed ~50,000 litres in under five weeks — at GMP quality.